Introduction
Acute thrombosis is a recognized complication of angioplasty and stenting of extracranial cerebral arteries 1, 2 . Treatment with pharmacological thrombolysis 3 has been reported. However, thrombolysis with either tissue plasminogen activator (tPA, Genentech) or Abciximab (Reopro, Eli Lilly) may not be adequate and expeditious in cases of large clot burden within the length of stent and carries significant haemorrhagic risks. The rheolytic thrombectomy device (AngioJet, Possis) that removes thrombus by Bernoulli effect, has the advantage of speed and low haemorrhagic risk. Since its invention in the early '90s 4,5, rheolytic thrombectomy technique has found success in the treatment of a large variety of vascular occlusive diseases in arteries, veins and grafts (table 1) . Its successful use in treating stent thrombosis of coronary arteries has also been reported 6, 7 . The rapid removal of thrombus with AngioJet catheter in patients with stroke is another frontier facing Rheolytic Thrombectomy of Acute Stent Thrombosis of Cervical Vertebral Artery consciousness. Suspected to have vasospasm, he had an angiogram, which revealed an intimal flap and a short segment of fixed >75% stenosis of the right vertebral artery at the level of C5 to C6. A 6 x 40 mm stent (SMART, Cordis) was placed over the dissection to restore the luminal diameter and normal blood flow. The patient's symptoms improved following the treatment. However, five days later, his symptoms recurred and there was new subarachnoid haemorrhage on CT. A third angiogram was performed and showed reconstitution of the distal left vertebral artery from the occipital and ascending pharyngeal collaterals. The right vertebral stent remained patent but there was a new < 50% stenosis at the lev- There is slow and partial filling of the left PICA pseudoaneurysm (arrow). C) The right vertebral artery dissection is stented. There is a filling defect in the stent (arrow head). D) The filling defect progresses to complete occlusion of the right vertebral artery. E) An Xpeedior rheolytic thrombectomy catheter has been advanced to the C1 portion of the right vertebral artery. The tip of the catheter is indicated by the thick arrow. F) Patency of the right vertebral artery is restored by rheolytic thrombectomy. figure 1B ). There was very slow and faint retrograde filling of the left vertebral pseudoaneurysm. Acute revascularization was indicated to reverse the progressive neurological decline given the evidence of worsening dissection and vertebrobasilar insufficiency. The patient was heparinized throughout the procedure, maintaining the activated clotting time 2.5 times his baseline. Because of his recent subarachnoid haemorrhages and partial filling of the pseudoaneurysm, prophylactic anti-platelet therapy was withheld. Two 6 x 40 mm overlapping SMART stents were placed to cover the dissection, resulting in initial reconstitution of the luminal diameter. However, five minutes later, a small intraluminal thrombus appeared along the posterior lateral margin of the recently placed stents at the level of C3-C4 (figure 1C), and progressed rapidly to complete occlusion of the right vertebral artery ( figure 1D ). The patient had diminutive bilateral posterior communicating arteries and was not expected to tolerate bilateral vertebral occlusion. To avoid the high haemorrhagic risk in a patient with recent subarachnoid haemorrhage and pseudoaneurysm and prolonged infusion required to remove the large clot burden using tPA or Abciximab, we decided to use the rheolytic thrombectomy device to rapidly recanalize the occluded right vertebral artery. An Xpeedior rheolytic thrombectomy catheter was advanced into the distal right vertebral artery along the .035 Amplatz guidewire (Cook) that was maintained after stenting (figure 1E). The catheter was slowly withdrawn through the clot while applying suction to remove the thrombus. The clot was removed and vascular patency was re-established after one pass ( figure 1F ). To prevent recurrent thrombosis and reduce the risks of distal embolism, a bolus of 16.8 mg of Abciximab was infused intravenously. There was no angiographic or symptomatic distal embolism ( figure  2A ). The patient was heparinized for five days then switched to maintenance aspirin. He made an excellent recovery despite several medical complications. After a ventriculoperitoneal shunt placement he was transferred to a rehabilitation facility on hospital day 32 without neurological deficit. At his six month follow-up angiogram, the intracranial branches were preserved ( figure 2B ) and the right vertebral stents remained patent ( figure 2C ). The left vertebral pseudoaneurysm had been obliterated. The patient was neurologically intact and had no difficulty with daily living.
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Discussion
This case demonstrates the feasibility of treating acute stent thrombosis in the cervical vertebral artery with rheolytic thrombectomy. Acute stent thrombosis is one of the recognized potentially fatal complications of angioplasty and stenting of extracranial carotid arteries. To our knowledge, this is the first reported case of acute stent thrombosis in the cervical vertebral artery. As angioplasty and stenting of extracranial cerebral arteries are gaining popularity, it becomes more and more important to recognize the potential serious complications and develop rescue options.
Stent thrombosis is thought to be mostly due to platelet aggregates on the rough surface of newly placed stent. Animal studies have demonstrated that platelets are the primary component of the thrombus, which may respond to anti-platelet therapy 8, 9 . Both oral antiplatelet agents 10 and Abciximab 11 have been shown by clinical studies to be effective at preventing acute stent thrombosis after coronary stent implantation. However, a recent randomized control study showed that prophylactic Abciximab does not reduce ischemic complications in patients undergoing elective carotid stenting but carries increased risk of haemorrhage 12 . These conflicting results need to be resolved to guide future therapy, particularly in patients with high haemorrhagic risks.
Rheolytic thrombectomy is a safe, rapid and efficient alternative to pharmacological thrombolysis in patients with bleeding contraindications. Developed by Possis, and first reported in an in vitro model by Drasler et Al 4, 5 , the AngioJet catheter has quickly gained clinical acceptance. A multicenter, prospective clinical trial in Europe supported its safety and efficacy in removing thrombus from native lower-extremity arteries and bypass grafts 13 . . A recent study demonstrated that rheolytic thrombectomy is cost-effective compared to the standard treatment of intracoronary urokinase for patients with acute myocardial infarction 15 . Two reports showed the feasibility of using AngioJet to treat stent thrombosis in coronary arteries 6, 7 . The technical success rate was reported from 59% to 100%. The major complications included moderate hemolysis, vessel dissection, perforation and distal embolism. The haemorrhagic risk of intracoronary rheolytic thrombectomy was only one quarter of that of urokinase, and mainly derived from heparinization. These studies have demonstrated that the rheolytic thrombectomy device is easy to use and highly effective. Although distal embolism occurs, as shown by an in vitro study 4 , the microemboli range from 2 to 15 micrometers and are too small to cause symptomatic tissue ischemia.
We observed several advantages of rheolytic thrombectomy in this case: it was fast, reducing the ischemic time; it was effective, capable of removing a large clot burden; it was safe, with little haemorrhagic risk and no significant distal embolism. The new Xpeedior rheolytic thrombectomy catheter offers excellent tracking along the .035 guide wire, and has a small tip that can fit into a 3 mm artery according to the manufacturer. We had no difficulty navigating the catheter into the vertebral artery and over the C1 curve under time pressure, demonstrating the technical possibility of its application in intracranial carotid artery and its major branches. Further development and modification of the device may permit greater versatility including the treatment of intracranial ischemic stroke patients.
Conclusions
This case demonstrates the feasibility of using rheolytic thrombectomy device to treat acute stent thrombosis in the cervical vertebral artery. Compared to pharmacological thrombolysis, rheolytic thrombectomy has the advantage of rapid removal of a large amount of thrombus with little haemorrhagic risk. Further study is warranted to evaluate its safety and efficacy for thrombectomy of both extracranial and intracranial cerebral arteries. 
